Osilodrostat effectively reduces hypercortisolism in patients with adrenal Cushing syndrome (CS), achieving biochemical response in up to 87.5% of patients treated longer than 12 weeks.
Patients previously treated with other steroidogenesis inhibitors show a significantly higher likelihood of responding to osilodrostat.
Osilodrostat therapy is associated with improvements in clinical parameters such as systolic blood pressure and body weight.
Adverse events are common, leading to treatment discontinuation in over half of affected patients, emphasizing the need for careful monitoring.
